Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Date of authorisation: 20/09/2017, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 30, Status: Authorised

Agenda - PDCO agenda of the 21-24 July 2026 meeting

Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): LysaKare, arginine,lysine, Date of authorisation: 25/07/2019, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Metalyse, tenecteplase, Date of authorisation: 23/02/2001, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Date of authorisation: 26/09/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Eltrombopag Accord, eltrombopag, Date of authorisation: 28/03/2025, Revision: 6, Status: Authorised